Sunmmary Tumour specimens from 23 patients with thyroid carcinoma, 22 patients with thyroid adenoma, 3 with Graves' disease, and tissues from 8 normal thyroid glands were analyzed by Southern blot hybridization for the physical state of c-myc and c-fos proto-oncogenes. In 4 patients, both the primary tumour and lymph node metastases were analyzed. No amplification or rearrangement of the two proto-oncogenes was detected. Total RNAs were also analyzed. Elevated levels of the 2.4kb c-myc RNA and of the 2.2kb c-fos RNA were found in 13/23 (57%) and 14/23 (61%) of the cancer patients, respectively. High levels of c-myc transcripts were more frequently found in thyroid carcinomas with unfavourable prognosis. Concomitant elevated levels of both c-myc and c-fos RNAs were found in 8 cancers. High levels of c-myc RNA were also found in 1 out of 22 specimens of adenoma, in 1 specimen of Graves' disease and in 2 normal thyroid glands. High levels of c-fos RNA were found in 20 of the 22 adenoma samples and in 2 out of 8 normal thyroid tissues. These data indicate that the overexpression of c-myc and c-fos genes is independent of an alteration of the loci. The high levels of c-fos found in adenoma may be associated with the differentiation state of these tumours.
Proto-oncogenes are thought to have regulatory roles in normal cell proliferation and differentiation. They may contribute to neoplastic transformation when there is an alteration in their function [Barbacid, 1986; Alitalo & Schwab, 1986; Cory, 1986) . The two proto-oncogenes c-myc and c-fos, which encode nuclear proteins, seem to have a crucial role in the control of cell proliferation. When quiescent fibroblasts are stimulated by peptide growth factors, c-fos and c-myc genes are rapidly and transiently induced (Muiiller et al., 1985; Verma et al., 1985) . Studies of c-fos expression in a variety of cell types and tissues at different stages of development have suggested that the c-fos gene product may play a role in cell differentiation (Muiller et al., 1985; Verma et al., 1985; Mufiller, 1986; Gonda & Metcalf, 1984) . However the characterization of the c-fos gene has only been carried out in a small number of fresh human cancers (Mavilio et al., 1986; Lehn et al., 1986) . By contrast, the c-myc gene was found to be rearranged, amplified and overexpressed in a wide variety of human cancers (Alitalo & Schwab, 1986; Riou et al,, 1984; Rothberg et al., 1984; Riou et al., 1985 Riou et al., ,1987 Guerin et al., 1985; Erisman et al., 1985; Terrier et al., 1985) . It was shown to be involved in the progression of various cancer (Barbacid, 1986; Little et al., 1983) in particular in cancers of the cervix (Riou et al., ,1987 , in which this oncogene is more frequently amplified and overexpressed in the more advanced stages (III and IV) than in the earlier ones (I and II) .
Long term prognosis of thyroid carcinoma is favourable, but is modulated by several parameters such as age, histologic characteristics, sex (Tubiana et al., 1985) . The EORTC prognostic index is a weighted factor which takes into account most of these parameters (Byar et al., 1979) . A pilot study (Terrier et al., 1985) showed that in one patient with thyroid carcinoma, there was an overexpression of the c-myc gene in the anaplastic component, in accordance with the severe prognosis of this histologic type; in contrast, the expression of this oncogene was normal in the papillary component. This prompted us to characterize the c-myc and c-fos proto-oncogenes in thyroid carcinomas and to analyze their expression in relation to prognosis and differentiation (Schlumberger et al., 1980 (Schlumberger et al., ,1986 .
Materials and methods
Tissue specimens Tissue specimens were obtained at thyroidectomy and immediately frozen in liquid nitrogen. They consisted of 23 specimens of primary thyroid cancers. In 4 of these patients metastatic lymph nodes were also obtained (Table I) (Heidinger & Sobin, 1974 prepared by the guanidinium thyocyanate method as described by Maniatis et al. (1982) . RNA and DNA were also prepared from N417 cell line originating from human small cell lung carcinoma which presents a 47 fold c-myc amplification and a high level of c-myc RNA (Little et al., 1983) .
Northern blots Denatured total RNA samples (10 Ig per well) were fractionated on a 1.2% formaldehyde agarose gel and transferred to a nitrocellulose filter. The filters were prehybridized and hybridized in stringent conditions as previously described (Maniatis et al., 1982 Figure 3 ). The blots were prehybridized, hybridized and washed as described for Northern blots.
Southern blots
Sample DNAs (5 pg) were digested with restriction endonuclease(s) and fractionated by electrophoresis on 1% agarose gels. The gels were denatured, treated as previously described (Maniatis et al., 1982) and DNA transferred to GeneScreenPlus (Dupont NEN) according to the prescription of manufacturer. The blots were prehybridized, hybridized and washed as described for Northern blots.
Probes
The probes used were the 1.4 kilobase pair (kb) EcoRI-Clal fragment of the human c-myc proto-oncogene encompassing exon 3 (Modjtahedi et al., 1985) , the 1.3kb BglII-BglII fragment of v-fos obtained from pFBJ2 plasmid (Curran et al., 1982) and the 1.7kb BglII-Xbal DNA fragment of the human I,h globin pseudogene (Fritsch et al., 1980) . The probes were labelled by 32P-dCTP (3000 Ci mmol-1) to a specific activity of 2-5 x 108 cpm ,ug-1 according to the nicktranslation technique (Maniatis et al., 1982) .
Quantitative analysis of the c-myc and c-fos proto-oncogenes The copy number of c-myc and c-fos proto-oncogenes in DNA samples was evaluated by microdensitometer tracings of autoradiograms. The f3I globin pseudogene was taken as a single copy gene internal control (Little et al., 1983 ) and used to estimate the copy number of the oncogenes in normal and tumour tissues. This method has been shown to allow a reliable quantitative measurement of copy numbers.
Quantitative analysis of the c-myc and c-fos gene expression The expression of proto-oncogenes was analyzed by Northern blot and slot blot hybridization of total RNA. The same blots were washed off for oncogene signals and rehybridized to a murine actin probe (Alonso et al., 1986 (Little et al., 1983) . Carcinomas were considered as overexpressed when the c-myc RNA level was found to be >3 times the level found in normal cells.
EORTC prognostic index
The EORTC prognostic index for thyroid carcinoma (Byar et al., 1979 
Results
The c-myc and c-fos loci were characterized in 12.5 and 9.0 kb DNA bands respectively, as expected for human DNA ( Figure 1 ) (Muller et al., 1985; Verma et al., 1985; Riou et al., 1984 Total RNAs were analyzed for the expression of c-myc and c-fos proto-oncogenes by Northern blot hybridization.
Transcripts of 2.4kb and 2.2kb were detected with c-myc and c-fos probes respectively in all specimens of thyroid carcinoma, adenoma, Graves' disease and normal thyroid glands (Figure 2) . Two minor bands with a migration close to that of 18S and 28S ribosomal RNAs were occasionally detected. Furthermore 13 of the 23 thyroid carcinomas exhibited high levels of c-myc RNA (Table I) corresponding to -3-to-20 fold the level observed in normal human tissues (lymphocytes, thyroid) (Figure 3) . The c-myc RNA levels were elevated in the 4 lymph node metastases as well as in the corresponding primary tumours. It was at high levels in 9 of the 18 tumours with lymph node metastases and in 3 out of the 5 tumours without lymph node metastases. Elevated c-myc RNA levels were also found in 1 out of 22 specimens of adenoma, 1 out of 3 Graves' disease and 2 out of 8 normal thyroid tissues.
Fourteen of the 23 thyroid carcinomas exhibited high levels of c-fos RNA. An overexpression of both c-fos and c-myc genes was found in 8 carcinomas. High levels of c-fos transcripts were found in 20 of the 22 adenomas and in the two normal thyroid tissues which contained also high levels of c-myc RNA.
A relationship has been sought between the overexpression of these oncogenes and the prognosis of the cancer patients by using the EORTC prognostic index (Byar et al., 1979) . The c-myc gene was -2 times more frequently overexpressed, in patients with an unfavourable EORTC prognostic index, than in those with a favourable index (X2 = 4.79 P < 0.03) (Tables II and III) . In contrast, the expression of the c-fos gene was not related with this index or with the regional lymph node status (Table III) (B) Same blot after the myc signal was washed off and the blot rehybridized to the v-fos probe (BglII-BglII DNA fragment). The c-fos transcripts migrated in a 2.2 kb band. High levels were found in adenoma (lane c) and in carcinomas (lanes f, h and j).
Two c-fos transcripts of sizes 3.2 and 10kb were found in N417 line, the 10kb transcript was not shown (lane a).
Same blot after the c-fos signal was washed off and the blot rehybridized to the murine actin probe. The actin transcripts migrated in a 2.0kb band.
Discussion
The present data clearly demonstrate that in fresh thyroid tissues, either normal or with various benign or malignant conditions, the structure of c-myc and c-fos proto-oncogenes is not altered and that these genes are neither amplified nor rearranged. Moreover no alteration was observed in the four lymph node metastases.
The c-myc and c-fos gene transcripts from normal or malignant tissues migrate as expected for human RNA (Verma et al., 1985; Muller et al., 1986; Gonda & Metcalf, 1984) . These data are at variance with the recent description of three distinct myc transcripts on a smaller number of patients studied (Yamashita et al., 1986) . of other primary origins (Riou et al., ,1987 Guerin et al., 1985) . In contrast the c-fos gene expression was not related to the prognostic variables. Recent studies in rat thyroid carcinoma lines have shown that TSH stimulates proto-oncogenes expression (Colletta et al., 1986; Dere et al., 1985 Dere et al., ,1986 Tramontano et al., 1986) . However in the present study, the overexpression of c-myc and c-fos genes was not related to previous TSH stimulation. Furthermore, no relationship was found between the overexpression of c-fos and functional characteristics (i.e., capacity of radioiodine uptake) of the neoplastic tissue. Unexpectedly elevated levels of c-myc RNA were detected in one adenoma, one Graves' disease and in two normal thyroid tissues. Recent data on the c-myc gene expression in developing human embryos suggest that the c-myc gene activity is not simply a marker of proliferative activity but reflects additional tissue-specific gene regulation operating during human embryogenesis (Pfeiffer-Ohlsson et al., 1985) . Several papers have shown that the high levels of c-myc RNA observed in some cell lines did not correspond to an overexpression of the c-myc gene but rather to a greater stability of the c-myc transcripts (Dani et al., 1984; Rabbitts et al., 1985) . In the present study such a mechanism cannot be ruled out.
In one patient, the c-fos gene was overexpressed in the anaplastic component, while c-fos RNA levels were normal in the papillary component surrounding the anaplastic tissue.
This result was unexpected since c-fos overexpression was shown to be associated with differentiation in cell systems (Muller et al., 1985; Verma et al., 1985; Muller, 1986) . The role of c-fos in thyroid tissue remains to be elucidated since markedly elevat-d levels were also found in adenomas; in these tissues the hypothesis that c-fos may accompany the differentiation state of these cells cannot be ruled out.
The regulation of c-myc and c-fos proto-oncogenes in normal thyroid tissues at different stages of differentiation is still unknown. It is therefore difficult to assess whether this overexpression can play a role in tumorigenesis; low levels of c-fos expression are associated with the transformation of fibroblasts whereas the c-fos proto-oncogene is highly expressed in some normal cells, for example in mature macrophages and in normal amniotic cells (Muller, 1986; Gonda & Metcalf, 1984) . The histological observation of thyroid sections show that tumoural as well as normal tissues are weakly associated with macrophages, eliminating the participation of these cells in the oncogene expression. In cell lines, the regulation of c-fos expression is complex (Greenberg et al., 1986) and is modulated by external signals . It is not known whether the high levels of transcripts are associated with high levels of protein expression as interestingly discussed for cervical cancers (Hendy-Ibbs et al., 1987) . A better understanding of the significance of these oncogene expressions in thyroid cancer requires further fundamental research; however the present data already underline the frequent existence of an overexpression of c-myc in the most malignant thyroid cancer, but it is not clear whether this dysregulation of the c-myc expression is the cause or the consequence of this malignancy.
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